EXPERIENCE THE RYZUMVI[™] DIFFERENCE

Reverse dilation and reimagine the post-dilation experience for patients.^{1,2}



© Ryzumvi[™] (phentolamine ophthalmic solution) 0.75%

INDICATION

RYZUMVI™ (phentolamine ophthalmic solution) 0.75% is indicated for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

SELECT IMPORTANT SAFETY INFORMATION


Warnings and Precautions

- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Please see additional Important Safety Information on back and full Prescribing Information in pocket.

DILATION IS A CRUCIAL BUT OFTEN DISRUPTIVE APPROACH TO PROTECT EYE HEALTH²⁻⁵

Have your patients ever refused dilation or had concerns about how long their eyes will remain dilated after their exam? You're not alone.^{6,7} POTENTIAL CHALLENGES MAY INCLUDE:




Patient hesitancy or refusal may stem from concerns around how long their pupils may remain dilated post-exam.⁴⁻⁷

A DISTINCT MECHANISM OF ACTION'

RYZUMVI[™] is the first and only relatively non-selective alpha-1 and alpha-2 adrenergic antagonist to reverse pharmacologically-induced mydriasis.¹

RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle and indirectly reverses the effects of muscarinic antagonists on the iris sphincter muscle, thus reducing pupil size after dilation.¹

How RYZUMVI works^{1,9}:



The dilation pathway ¹	The constriction pathway ¹
RYZUMVI reversibly binds to alpha-1 adrenergic receptors on the radial iris dilator muscle, reducing pupil diameter and directly antagonizes the mydriatic effect of an alpha-1 adrenergic agonist.	RYZUMVI indirectly reverses dilation induced by muscarinic antagonist effects on the iris sphincter muscle.

RYZUMVI reversed pupil dilation regardless of whether phenylephrine, tropicamide, or Paremyd[®] (hydroxyamphetamine hydrobromide and tropicamide) was used.^{1,10,11}

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

• Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.




Please see full Prescribing Information in pocket.


RAPID DILATION REVERSAL IS NOW AVAILABLE'

The only available FDA-approved eye drop to rapidly reverse dilation, generally by 90 minutes.¹

RYZUMVI[™] was evaluated across 2 randomized, vehicle-controlled, double-masked studies in which patients (N=553) aged 12 to 80 years who had mydriasis induced by instillation of phenylephrine, tropicamide, or Paremyd[®] (hydroxyamphetamine hydrobromide and tropicamide) were administered 2 drops (study eye) or 1 drop (fellow eye) of either RYZUMVI or placebo one hour after instillation of the mydriatic agent.¹



PERCENTAGE OF PATIENTS RETURNING TO ≤0.2 MM OF BASELINE PUPIL DIAMETER¹



30

The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.¹

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
- Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

WELL-TOLERATED IN CLINICAL STUDIES^{1,10,11}

The safety and tolerability of RYZUMVI were studied and evaluated in 642 patients enrolled in the MIRA trials. There are no known contraindications for RYZUMVI.¹

MOST COMMON ADVERSE REACTIONS^{1,10,11}:





Conjunctival hyperemia No moderate or severe conjunctival hyperemia cases were reported in RYZUMVI clinical trials.

Most (>94%) side effects were mild, including eye discomfort and redness. No serious side effects related to RYZUMVI were reported in clinical trials.^{10,11}

Warning: RYZUMVI is not recommended when active ocular inflammation (e.g. iritis) is present because adhesions (synechiae) may form between the iris and the lens.¹

There are no retinal-specific warnings or contraindications with RYZUMVI, and no retinal detachment cases were reported in RYZUMVI clinical trials.^{1,10,11}



6%

Dysgeusia

REVERSE DILATION WITH JUST 1-2 DROPS'

Looking to improve the post-dilation experience? Order RYZUMVITM—the only commercially available FDA-approved product that rapidly reverses dilation.^{1,10,11}

One single-patient-use vial should be dispensed for each patient, and it can be used to dose both eyes. Discard the single-patient-use vial immediately after use.¹

PATIENTS AGED 12 YEARS AND OLDER¹



- Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure
- If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop

PATIENTS AGED 3-11 YEARS¹



1 drop

 Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure

The efficacy of RYZUMVI was similar for all age ranges, including pediatric subjects aged 3 to 17 years. Pediatric subjects aged 12 to 17 years (n=27) were treated in MIRA-2 and MIRA-3, and pediatric subjects aged 3 to 11 years (n=11) were treated in MIRA-4.¹

As an eye care professional, the decision to use one or two drops of RYZUMVI is based on your discretion and judgment.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- **Potential for Eye Injury or Contamination:** To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
- Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.



RYZUMVI: 0.75% phentolamine ophthalmic solution

Does not contain an antimicrobial preservative. Stable topical eye drops are available in a single-patient-use vial, with no mixing required.¹

How RYZUMVI is supplied¹

RYZUMVI is a sterile, clear, and colorless topical ophthalmic solution and comes in a translucent, low-density polyethylene, single-patient-use vial (0.31 mL fill).¹

PACKAGING¹

- Each carton contains 30 single-patient-use vials of RYZUMVI
- One strip of 5 single-patient-use vials is packaged into a foil pouch, with 6 foil pouches in a carton

STORAGE AND REFRIGERATION¹

- Store refrigerated at 2°C to 8°C (36°F to 46°F), not to exceed the expiration date printed on the carton and pouch
- Protect from freezing
- After opening the foil pouch, the product may be stored at 25°C (68°F to 77°F) and should be used within 14 days, not to exceed the expiration date printed on the vial



ORDER FROM SIGMA PHARMACEUTICALS

WWW.SIGMAPHARMACEUTICALS.COM 800-779-3784



Please see full Prescribing Information in pocket.

DON'T LET DILATION DISRUPT THEIR ENTIRE DAY

With RYZUMVI[™], you can offer faster eye dilation reversal to help address patient concerns and improve the post-dilation experience.¹





Rx Only

NDC: 83368-075-30

0

Ryzumvi

Ocuphire

aining 5 single-patient-use vials each

(phentolamine ophthalmic solution) 0.75% FOR TOPICAL USE IN THE EYES

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
- **Potential for Eye Injury or Contamination:** To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
- Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.

Adverse Reactions

The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).

Please see full Prescribing Information in pocket.

References: 1. RYZUMVI (phentolamine ophthalmic solution). Prescribing Information. Ocuphire. 2. Boyd K. Mendoza O. What are dilating eye drops? American Academy of Ophthalmology. Available at: https://www.aao.org/eye-health/drugs/dilating-eyedrops. Accessed February 8, 2024. 3. American Academy of Ophthalmology. Comprehensive adult medical eye evaluation preferred practice pattern. *American Academy of Ophthalmology.* 2020;1-29. 4. Paremyd. Prescribing Information. Akorn, Inc. 5. Tropicamide. Prescribing Information. Alcon Laboratories, Inc. 6. Murphy J. How often do you dilate? Review of Optometry. Available at: https://www.reviewofoptometry.com/article/how-often-do-you-dilate. Accessed February 8, 2024. 7. American Optometric Association. 2 points to keep in mind when patients decline dilation. Available at: https://www.aca.org/news/practice-management/billing-and-coding/2-points-to-keep-in-mind-when-patients-decline-dilation? Accessed February 8, 2024. 8. Softing Hataye AL Is it necessary to have my eyes dilated during every eye exam? Mayo Clinic. Available at: https://www.mayoclinic.org/healthy-lifestyle/adult-health/expert-answers/eye-dilation. Accessed February 8, 2024. 9. Smith PG. Neural regulation of the pupil. *Encyclopedia of Neuroscience*. 2024. 10. Viatris. Data on file. OPI-NYXRM-301 (MIRA-2) Clinical Study Report. October 25, 2021. 11. Viatris. Data on file. OPI-NYXRM-302 (MIRA-3) Clinical Study Report. August 10, 2022.

© 2024 Viatris Inc. and/or its affiliates. All rights reserved. Viatris and the Viatris logo are trademarks of Mylan Inc., a Viatris Company. RYZUMVI and the Ryzumvi Logo are trademarks of Ocuphire Pharma Inc., licensed to the Viatris Companies. Paremyd® is a registered trademark of Akorn Operating Company LLC.